Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LiveSpo X-secret is a vaginal spray probiotic suspension containing 5 billion CFU of three Bacillus strains: Bacillus subtilis, Bacillus clausii, and Bacillus coagulans. Developed by AnaBio Technologies, it is designed as a supportive treatment for vaginal infections, including vaginitis and sexually transmitted infections (STIs). The product functions by restoring the balance of the vaginal microbiota, inhibiting the growth of pathogenic bacteria, viruses, fungi, and protozoa, and regulating pro-inflammatory cytokines. The use of Bacillus spores provides enhanced stability in acidic and thermal environments compared to traditional Lactobacillus-based probiotics, and the spray delivery system is intended to offer a faster onset of action compared to oral or suppository formulations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on LiveSpo X-secret.